Edap TMS SA has issued its initial worldwide revenue guidance for 2026 following a record performance in 2025. The company reported preliminary unaudited results indicating 36% to 38% year-over-year growth in HIFU revenue for 2025, with Focal One system placements increasing by 69% annually and U.S. procedure volumes rising by 28% year-over-year in the fourth quarter. For the first time, HIFU revenue is expected to constitute more than half of Edap’s annual revenue, signifying a major shift in the company’s revenue composition and highlighting the growing adoption of its Focal One system for prostate cancer treatment. Edap’s non-core revenue for 2025 is expected to range between $32.7 million and $33.1 million. The company anticipates continued revenue growth in 2026, supported by an expanding global pipeline and increasing procedure utilization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edap TMS SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001158741-en) on January 12, 2026, and is solely responsible for the information contained therein.